GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was KRW 0.00031 million compared to KRW 0.00023 million a year ago. Net loss was KRW 20,684.69 million compared to net income of KRW 19,327.07 million a year ago. Basic loss per share from continuing operations was KRW 1,812 compared to basic earnings per share from continuing operations of KRW 1,693 a year ago. Basic loss per share was KRW 1,812 compared to basic earnings per share of KRW 1,693 a year ago.